Mesoblast (NASDAQ:MESO) Shares Gap Down – Should You Sell?

Mesoblast Limited (NASDAQ:MESO)’s share price gapped down before the market opened on Thursday . The stock had previously closed at $11.45, but opened at $10.95. Mesoblast shares last traded at $10.95, with a volume of 49,100 shares.

Wall Street Analysts Forecast Growth

MESO has been the subject of several analyst reports. StockNews.com lowered Mesoblast from a “hold” rating to a “sell” rating in a research report on Wednesday, September 4th. Jefferies Financial Group raised Mesoblast from a “hold” rating to a “buy” rating in a research report on Thursday, August 29th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Mesoblast in a report on Thursday, August 29th. Finally, Maxim Group upgraded Mesoblast from a “hold” rating to a “buy” rating and set a $12.00 target price for the company in a report on Tuesday, September 24th. One analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $11.50.

Mesoblast Price Performance

The company’s 50-day simple moving average is $9.75 and its 200 day simple moving average is $7.93. The company has a debt-to-equity ratio of 0.21, a current ratio of 1.18 and a quick ratio of 1.18.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. GAMMA Investing LLC increased its holdings in Mesoblast by 50.1% during the 2nd quarter. GAMMA Investing LLC now owns 4,981 shares of the company’s stock worth $34,000 after purchasing an additional 1,663 shares during the period. Signaturefd LLC grew its position in shares of Mesoblast by 128.7% during the third quarter. Signaturefd LLC now owns 5,506 shares of the company’s stock worth $45,000 after buying an additional 3,099 shares in the last quarter. Perkins Coie Trust Co purchased a new stake in shares of Mesoblast during the second quarter worth approximately $68,000. Pine Valley Investments Ltd Liability Co acquired a new stake in Mesoblast in the second quarter valued at approximately $80,000. Finally, Rathbones Group PLC purchased a new position in Mesoblast in the second quarter worth approximately $95,000. 1.43% of the stock is currently owned by hedge funds and other institutional investors.

Mesoblast Company Profile

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.